 |
Acromegaly Treatment Market
Acromegaly is an uncommon illness that affects a patient's external and internal organs and is brought on by the pituitary gland's overproduction of growth hormone. Though benign pituitary tumors (adenomas) are typically to blame, the hypothalamus' inability to effectively regulate growth hormone-secreting cells can occasionally result in acromegaly symptoms. The visual indications of this disorder include abnormally enlarged hands, arms, feet, legs, and heads, as well as subtle changes to face features including the brow, lower jaw, and nose. Acromegaly that is left untreated can cause fatal consequences like cardiomyopathy and ventricular arrhythmia. MRI and CT scan imaging of tumors and blood tests to evaluate growth hormone or insulin-like growth factor levels are frequently used diagnostic.
Somatostatin,
Glucocorticoid Receptor Inhibitors, and other Off-Label medications are further
subcategorized under the Acromegaly treatment. Hospital pharmacies, retail
pharmacies, and internet pharmacies make up the three segments of the Acromegaly Treatment Market for the treatment
of Cushing's disease and acromegaly.
High blood pressure, abdominal obesity, a round, red face, a mass of fat between the shoulders, weakened muscles and bones, acne, brittle skin, and other symptoms are all part of Cushing's syndrome. Pituitary adenoma and multiple endocrine neoplasias are the two conditions that most often lead to Cushing's syndrome.
Acromegaly
Treatment Market
is characterized by symptoms that include enlargement of the hands, feet, forehead,
jaw, nose, and other body parts that cause joint pain, thickening of the skin,
depth of the voice, migraines, and visual issues. Hypertension and type 2
diabetes are additional problems. The production of too much growth hormone is
another factor in acromegaly (GH). The pituitary gland produces excess
growth hormone in the majority of cases of acromegaly, which is usually caused
by a benign tumor called a pituitary adenoma. Acromegaly Treatment Market affects roughly 2 to 3 persons per
million people annually.
Key Players
The major players in the market for acromegaly treatments include Pfizer Inc., Novartis Pharma AG, GlaxoSmithKline plc, Midatech Pharma PLC, Strongbridge Biopharma plc, Chiasma Inc, Aegis Therapeutics LLC, Amryt Pharma plc, Antisense Therapeutics Ltd, Crinetics Pharmaceuticals Inc, Dauntless Pharmaceuticals Inc, and Ipsen Biopharmaceuticals Inc.
Comments
Post a Comment